For Trade and Medical Media Only



(BUSINESS WIRE)--Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026.

The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings.

ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As pre ... Read more »

ZUG, Switzerland - Friday, 23. October 2026


The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2
The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7
This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide


(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary imp ... Read more »

NEW YORK -
(BUSINESS WIRE) -- Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania.

In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage.

The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ.

As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project.

Social Media

LinkedI ... Read more »

OSAKA, Japan & CAMBRIDGE, Mass. - Friday, 23. October 2026 AETOSWire

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026
Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric Cancer
Findings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers


(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/G ... Read more »

Dashen Bank and ShebaMiles have launched a Platinum co-branded Mastercard debit card in Ethiopia, combining secure payments, digital access, loyalty benefits and premium travel privileges in one offering.

Issued by Dashen Bank and powered by Mastercard, the card is linked to Ethiopian Airlines’ ShebaMiles loyalty program. It enables customers to use one card for everyday and travel-related payments while accessing benefits including airport lounge access, airport fast track and global data roaming, in addition to the miles they earn in the air.

The collaboration combines Ethiopian Airlines’ travel network and loyalty program, Dashen Bank’s issuing capabilities, customer reach and Super App, and Mastercard’s global payment network, technology and premium card benefits.

Shehryar Ali, senior vice president and country manager for East Africa and Indian Ocean Islands at Mastercard, said: “Travel is increasingly becoming a connected digital experience, and consumers ... Read more »

SAN CARLOS, Calif. - Friday, 23. October 2026 AETOSWire

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 months

TEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy

(BUSINESS WIRE) -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2 ... Read more »

Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows

(BUSINESS WIRE)--NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows.

Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use c ... Read more »

IRVINE, Calif. -
Leveraging the Waqoo Group’s research and technology ecosystem to establish a new personal baseline for proactive health and longevity



(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it has commenced in-house development of a test designed to estimate an individual’s biological age using DNA methylation analysis.

Development will be led by the Company’s AI and longevity-focused subsidiary, SBC AI Longevity Innovation, Inc. The initiative will leverage the regenerative medicine research and technology base established by Waqoo, Inc. (TOKYO: 4937), a consolidated subsidiary of SBC Medical, and its subsidiary Cell Pro Japan Co., Ltd. (together, the “Waqoo Group”). The test aims to provide insight into an individual’s physical condition that chronological age ... Read more »

ZUG, Switzerland - Ad hoc announcement pursuant to Art. 53 LR (BUSINESS WIRE) -- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for the first nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio ... Read more »

MARLBOROUGH, Mass. - Tuesday, 13. October 2026 AETOSWire

ExaGrid Achieves 23rd Consecutive Quarter of Free Cash Flow, EBITDA, and P&L Positive Operations



(BUSINESS WIRE)--ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the fastest backups, fastest restores, largest backup storage scale-out system with deduplication, and the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it had its best ever third quarter for bookings and revenue in the quarter ending September 30, 2026, with double-digit revenue growth over Q3 of 2025 and double-digit revenue growth for the first nine months of 2026 over 2025. ExaGrid has exceeded its plan in all three quarters of 2026 and is ahead of plan on its way to a record bookings and revenue year. ExaGrid’s growth rate is accelerating.

In addition, ExaGrid remained P&L, EBITDA, and free cash flow positive f ... Read more »